¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time factor effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
¿µ¹® bleeding time ÇÑ±Û ÃâÇ÷½Ã°£
¼³¸í   
  ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù.
  
  ÃâÇ÷½Ã°£Àº À§¿¡¼­ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼­ Ã¹¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼­¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁִ º®µ¹¿¡ ÇØ´çÇϴ Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ Àִ °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù.
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • curative effect
    Ä¡·áÈ¿°ú
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
  • cavitation effect
    °øµ¿È¿°ú
  • ceiling effect
    ÃÖ°íÈ¿°ú
  • delayed effect
    Áö¿¬È¿°ú
  • detergent effect
    ¼¼Ã´È¿°ú, Á¤È­È¿°ú
  • deterministic effect
    È®Á¤ÀûÈ¿°ú
  • diabetogenic effect
    ´ç´¢º´À¯¹ßÈ¿°ú
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • effect
    È¿°ú
  • greenhouse effect
    ¿Â½ÇÈ¿°ú
  • healthy worker effect
    °Ç°­±Ù·ÎÀÚÈ¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conduction time
    Àüµµ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • time cluster
    ½Ã°£Áý¶ô¼º
  • time cue
    ½Ã°£½ÅÈ£ÀÎÀÚ
  • time compensation curve
    ½Ã°£º¸»ó°î¼±
  • time-activity curve
    ½Ã°£¹æ»ç´É°î¼±
  • time-kill curve
    ½Ã°£»ç¸ê°î¼±
  • time-motion curve
    ½Ã°£¿îµ¿°î¼±
  • time-place cluster
    ½Ã°£Áö¿ªÁý¶ô¼º
  • dead time
    ºÒÀÀ½Ã°£
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • interaural time difference
    ¾ç±Í°£µµ´Þ½Ã°£Â÷
  • real time display
    ½Ç½Ã°£Ç¥½Ã, ½ÇÁ¦½Ã°£Ç¥½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activated clotting time
    Ȱ¼ºÈ­ÀÀ°í½Ã°£
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • appearance time
    ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • arm to tongue time test
    ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anticurare effect
    Ç×Å¥¶ó·¹ÀÛ¿ë.
  • antioxidant effect
    Ç×»êÈ­È¿°ú(¡­üùÍý).
  • antitoxemic effect
    Ç×µ¶Ç÷ÁõÈ¿°ú.
  • antitussive effect
    ÁøÇØÈ¿°ú(òåú¦üùÍý).
  • back-pressure effect
    ÈĹæ¾Ð·ÂÈ¿°ú ¡ìÆóÁ¤¸Æ¿ïÇ÷¡í.»ý¸®ÈĹæ¾Ð·ÂÀÛ¿ë(ý­Û°äâæ³íÂéÄ).
  • bacteriostatic effect
    Á¤±ÕÈ¿°ú(¡­üùÍý).
  • beam hardening (effect)
    ºö°æÈ­È¿°ú
  • beam softening (effect)
    ºö¿¬È­È¿°ú
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú)
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú).
  • biologic effect
    »ý¹°ÇÐÀû È¿°ú
  • biological effect
    »ý¹°ÇÐÀû È¿°ú
  • blow back effect
    (ÃѱâÀÇ) ÈÄdz(ý­ù¦) È¿°ú
  • bridle effect
    °í»ßÈ¿°ú, Á¦¾îÈ¿°ú
  • cardiac effect
    ½É(Àå)È¿°ú(ãýíôüùÍý).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • resolving time
    "ºÐ¸®½Ã°£, ÇØ»ó½Ã°£"
  • retention time
    ¸Ó¹«¸§ ½Ã°£
  • rotational relaxation time
    ȸÀü À̿Ͻð£(üÞï®ì¬èÐãÁÊà)
  • thermal death time
    ¿­»ç½Ã°£ (æðÞÝãÁÊà)
  • time constant
    ½Ã°£»ó¼ö (ãÁÊàßÈâ¦)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • transient time
    °úµµ±â ½Ã°£(ΦԤѢãÁÊà)
  • turnover time
    Àüȯ½Ã°£(ï®üµãÁÊà)
  • zero time binding DNA
    ¿µ½Ã(çÍãÁ) °áÇÕ(Ì¿ùê) DNA
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
  • anomeric effect
    ¾Æ³ë¸Ó¿µÇâ(ç¯úÂ)
  • asymmetry effect
    ºÎÀçÈ¿°ú(Üôî²üùÍý)
  • Blinks effect
    ºí¸°Å©½º È¿°ú(üùÍý) (ÔÒ) chromatic transient
  • Bohr effect
    º¸¾î È¿°ú(üùÍý)
  • charge effect
    ÀüÇÏÈ¿°ú(ï³ùÃüùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Doppler effect
    µµÇ÷¯È¿°ú
  • effect
    È¿°ú, ÀÛ¿ë
  • entry slice effect
    À¯ÀԴܸéÈ¿°ú
  • fast scan effect
    °í¼Ó½ºÄµÈ¿°ú
  • Gibbs effect
    ±é½º È¿°ú
  • gradient echo effect
    °æ»ç¿¡ÄÚÈ¿°ú
  • gradient induced phase shift effect
    °æ»çÀ¯µµ À§»óº¯À§È¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
  • immediate effect
    Áﰢȿ°ú, Áï½ÃÈ¿°ú
  • in-flow effect
    À¯ÀÔ È¿°ú
  • iron effect
    öȿ°ú
  • mach effect
    ¸¶ÇÏÇö»ó
  • magnetization transfer effect
    ÀÚÈ­Àü´ÞÈ¿°ú
  • main effect
    ÁÖÀÛ¿ë
  • mass effect
    Á¾±«È¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CPE Cytopathic effect
ES Effect Size
HWE Healthy Worker Effect
ISFET Ion Sensitive Field Effect Transistor
LOAEL Lowest Observed Adverse Effect Level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
  • fast time constant circuit
    °í¼Ó ½Ã°£ °íÁ¤ ȸ·Î
  • first-time dental patient
    óÀ½ ³»¿øÇÑ È¯ÀÚ
  • hardening time
    °æÈ­ ½Ã°£
    Ä¡°ú¿ë ÀλóÀç ¶Ç´Â ¼®°í°¡ µüµüÇÏ°Ô ±»´Âµ¥ °É¸®´Â ½Ã°£.
  • heating and cooling temperature-place-time profile
    °¡¿­ ¹× ³Ã°¢ ¿Âµµ-À§Ä¡-½Ã°£ Çü
  • inversion time
    ¿ªÀü ½Ã°£
  • left ventricular ejection time
    Á ½É½Ç ±¸Ç÷ ±â°£
  • mixing time
    ±³¹Ý ½Ã°£, È¥ÇÕ ½Ã°£
    µÎ °¡Áö ÀÌ»óÀÇ Àç·á¸¦ È¥ÇÕÇÒ ¶§ ¼Ò¿äµÇ°Å³ª ÁöÄÑ¾ß ÇÏ´Â ½Ã°£À¸·Î, Ä¡°ú ¿µ¿ª¿¡¼­´Â ¼®°í Àç·á, ½Ã¸àÆ®, ¼öÁö, ÀλóÀç, ¸Å¸ôÀç µî¿¡¼­ ÁؼöµÇ¾î¾ß ÇÒ ½Ã°£. Àç·áÀÇ ¹°¸®Àû ¼ºÁú¿¡ ¿µÇâÀ» ÁØ´Ù.
  • operative time
    ¼ö¼ú ½Ã°£
  • partial prothrombin time
    ºÎºÐ ÇÁ·ÎÆ®·Òºó ½Ã°£
  • persistence time
    Áö¼Ó ½Ã°£
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • prolonged bleeding time
    ¿¬ÀåµÈ ÃâÇ÷ ½Ã°£
  • real time acquisition
    ½Ç½Ã°£ ȹµæ
  • real time image
    ½Ç½Ã°£ ¿µ»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
rise time The time required for a pulse or echo to rise from 10% to 90% of its peak amplitude.
(05 Mar 2000)
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
clotting time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
collision time <radiobiology> Typical time which passes between two consecutive collision events for a given particle. Inverse of the collision frequency, equal to the mean free path divided by the particle's velocity. In plasmas, the (Coulomb) collision time decreases with increasing density, and increases with increasing temperature.
(09 Oct 1997)
whole blood coagulation time Measurement of the time required by whole blood to produce a visible clot. Factors that could influence the test are all but III, vii, and xiii. Activation may be by contact with the glass tube or exposure to diatomaceous earth. Delay of onset of coagulation may be achieved by use of nonwettable plastic or silicone-coated glass tubes. It is used for monitoring heparin therapy and as a bedside screening test for deficiencies in the intrinsic coagulation pathway. "activated coagulation time" is sometimes referred to as act.
(12 Dec 1998)
confinement time <radiobiology> There are several types. The general definition is tau = [total]/[loss per unit time], hence Tau_E = [total energy]/[energy loss per unit time]. Tau_[E, N,.] is the amount of time the plasma is contained (for example, by magnetic fields) before its [energy (E), particles (N or P)] leak / dissipate away. The different types are, in general, similar but not equal. (N.B., Tau_E is NOT electron confinement time!)
(09 Oct 1997)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
half-time The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear.
Compare: half-life.
(05 Mar 2000)
prothrombin time Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
  • effect
    °á°ú,¿µÇâ,È¿°ú,½Ç½Ã,ÃÊ·¡ÇÏ´Ù
  • side effect
    ºÎÀÛ¿ë
  • Compton effect
    ÄÞÇÁÅÏ È¿°ú(±¤ÀÚ¿Í ÀüÀÚÀÇ Åº¼º »ê¶õ)
  • Donald Duck effect
    µµ³Îµå ´ö È¿°ú(¿ìÁÖ ºñÇàÁßÀÇ À½¼ºÀÇ °íÀ½È­ Çö»ó)
  • Doppler effect
    µµÇ÷¯ È¿°ú 
  • Gunn effect
    ¿µ±¹ Å»ýÀÇ ¹°¸®ÇÐÀÚ J.B.Gunn ÀÇ À̸§¿¡¼­
  • Raman effect
    ¶ó¸¸ È¿°ú(ºûÀÌ Åõ¸íÇÑ ¸ÅÁúÀ» Åë°úÇÒ ¶§,»ê¶õÇÏ¿© ºûÀÇ ÀϺΠÆÄÀåÀÌ º¯È­ÇÏ´Â Çö»ó)
  • cause-and-effect
    Àΰú °ü°èÀÇ
  • echo effect
    ¸Þ¾Æ¸® È¿°ú(¾î¶² ÀÏÀÌ µÚ´Ê°Ô µÇÇ®ÀÌ µÇ°Å³ª,±× °á°ú°¡ ´Ê°Ô ³ªÅ¸³ª´Â µîÀÇ Çö»ó)
  • effect
    °á°ú;¿µÇâ;È¿°ú;À¯È¿;´À³¦;Àλó;ºû±òÀÇ ¹èÇÕ;ÃëÁö;´ëÀÇ;¿Ü°ü;°á°ú¸¦ °¡Á®¿À´Ù;´Ù;¸ñÀûÀ» ÀÌ·ç´Ù
  • electrooptic effect
    (Àü)Àü±â ±¤ÇÐ È¿°ú
  • glasshouse effect
    =GREENHOUSE EFFECT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á